Stock Wars: AstraZeneca Vs. Pfizer
Benzinga’s Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is the better investment.
In this week’s installment, we take a look at two pharmaceutical giants at the forefront of the COVID-19 vaccine development:
AstraZeneca plc (NASDAQ:AZN) and
Pfizer Inc. (NYSE:PFE).
The AstraZeneca Experience: AstraZeneca was founded in 1999 through the merger of the Swedish Astra AB, which dated back to 1913, and Britain’s Zeneca Group plc, with the merged company setting up its headquarters in Britain.
During the COVID-19 crisis, AstraZeneca teamed with scientists at Oxford University to create a vaccine to stop the spread of the pandemic. The first doses of the vaccine given to patients outside of clinical tests took place in the U.K. in January, and one month later the World Health Organization issued interim guidance and recommended the vaccine for all adults.
Pfizer Says Priority Review Period Extended For NDA For Abrocitinib
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said Wednesday the FDA has extended the review period for the New Drug Application for its atopic dermatitis drug candidate Abrocitinib, with decision date extended by three months to early third quarter.
The review period for the Supplemental New Drug Applications for XELJANZ/ XELJANZ XR (tofacitinib) for the treatment of adult patients with active ankylosing spondylitis (AS) has also been extended by three months with a decision expected in early third qurter, 2021.
XELJANZ (tofacitinib) is approved in four indications including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC), and polyarticular course juvenile idiopathic arthritis (pcJIA).
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Pfizer Inc. today announced that the U.S. Food and Drug Administration has extended the priority review period for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act goal date has been extended three months to early Q3 2021. The FDA has also extended the review period for the Supplemental New Drug … Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application (NDA) for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act (PDUFA) goal date has been extended three months to early Q3 2021.
Date Time
Share
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for Treatment of Moderate to Severe Atopic Dermatitis
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application (NDA) for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act (PDUFA) goal date has been extended three months to early Q3 2021.
The FDA has also extended the review period for the Supplemental New Drug Applications (sNDAs) for XELJANZ